J.P. Morgan Sticks to Their Hold Rating for Regeneron (REGN)

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Regeneron (REGN) yesterday. The company’s shares closed yesterday at $396.63, close to its 52-week high of $416.49.

According to TipRanks.com, Kasimov is a 1-star analyst with an average return of -0.4% and a 38.3% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Allogene Therapeutics Inc, and Jounce Therapeutics Inc.

Currently, the analyst consensus on Regeneron is a Moderate Buy with an average price target of $416.08, a 4.9% upside from current levels. In a report released yesterday, Cowen & Co. also maintained a Hold rating on the stock with a $385 price target.


See today’s analyst top recommended stocks >>

Based on Regeneron’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $595 million. In comparison, last year the company had a net profit of $174 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regeneron Pharmaceuticals, Inc. engages in the discovery, invention, development, manufacture, and commercialization of medicines for the treatment of serious diseases. It products include the following brands: EYLEA, Dupixent, Praluent, Kevzara, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.